GPI Presented Research
The National Pricing & Reimbursement Process in China, a 2021 update
The research looks into detail at The Chinese National Reimbursement Drug List (NRDL) and reforms that have resulted in changes to the reimbursement process and how new drugs are launched within the market.
List prices for Medicare negotiation-eligible medicines targeted by Build Back Better
GPI attended ISPOR last month, in Washington D.C, and had the opportunity to present three research abstracts, including “List prices for Medicare negotiation-eligible medicines targeted by Build Back Better drug pricing provisions estimated to be reduced by over 40% on average.”
Forecasting Drug Price for Reimbursement By Utilizing a Value-Price Relationship
GPI attended ISPOR (May 22), in Washington D.C, and had the opportunity to present three research abstracts, including our drug price forecasting study, utilizing a value-price relationship
The impact of Value-Based Pricing (VBP) vs International Reference Pricing (IRP)
GPI attended ISPOR last month, in Washington D.C, and had the opportunity to weigh in on this discussion with some of our data comparing two widely-used pricing levers, HTA-based value-based pricing (VBP) and International Reference Pricing (IRP).
Value Assessment & Price Forecasting
Find out more about value assessment and price forecasting, and how GPI can optimise your pricing strategy with our award winning methodology GPI horizon
Find out more
Engage with us
Register your interest
in GPI solutions
Sign up for